Oncocyte (IMDX) FDA Approvals $5.37 -0.03 (-0.56%) Closing price 04:00 PM EasternExtended Trading$5.18 -0.19 (-3.61%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock Oncocyte's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Oncocyte (IMDX). Over the past two years, Oncocyte has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as GraftAssureDx. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. GraftAssureDx FDA Regulatory Events GraftAssureDx is a drug developed by Oncocyte for the following indication: test kit clinical trial for its planned in vitro diagnostic (IVD). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Provided Update - March 3,2026Provided Update Drug: GraftAssureDxAnnounced Date: March 3, 2026Indication: test kit clinical trial for its planned in vitro diagnostic (IVD)AnnouncementInsight Molecular Diagnostics Inc. announced that in February the company completed several major milestones to support the GraftAssureDx™ test kit clinical trial for its planned in vitro diagnostic (IVD) De Novo submission to the U.S. Food and Drug Administration (FDA) and also received its ISO 13485 certification.AI SummaryIn February, Insight Molecular Diagnostics announced several major milestones to support the GraftAssureDx test kit and its planned in vitro diagnostic (IVD) De Novo submission to the U.S. Food and Drug Administration. The company completed a three-site reproducibility study at Tampa General Hospital, Mayo Clinic, and Baylor Scott & White Health. It also said it collected what it believes are sufficient clinical samples to support the statistical analysis needed for the submission. On Feb. 26, Insight received ISO 13485 certification from TÜV SÜD. That certification confirms a regulator-aligned quality management system, helps enable near-term IVD submissions in the U.K., and paves the way for an EU IVD-R filing. The company says the certification should reduce the risk of surprises during regulatory review and lower quality risk for future manufacturing. Insight is finishing internal analytical performance testing; of roughly 12,000 instrument and assay cycles needed for the FDA package, about 340 remain. The company aims to make GraftAssureDx available for clinical use beginning in 2026 to expand access to transplant organ health testing.Read Announcement Oncocyte FDA Events - Frequently Asked Questions Has Oncocyte received FDA approval? As of now, Oncocyte (IMDX) has not received any FDA approvals for its therapy in the last two years. What drugs has Oncocyte submitted to the FDA? In the past two years, Oncocyte (IMDX) has reported FDA regulatory activity for GraftAssureDx. What is the most recent FDA event for Oncocyte? The most recent FDA-related event for Oncocyte occurred on March 3, 2026, involving GraftAssureDx. The update was categorized as "Provided Update," with the company reporting: "Insight Molecular Diagnostics Inc. announced that in February the company completed several major milestones to support the GraftAssureDx™ test kit clinical trial for its planned in vitro diagnostic (IVD) De Novo submission to the U.S. Food and Drug Administration (FDA) and also received its ISO 13485 certification." What conditions do Oncocyte's current drugs treat? Currently, Oncocyte has one therapy (GraftAssureDx) targeting the following condition: test kit clinical trial for its planned in vitro diagnostic (IVD). More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Amylyx Pharmaceuticals FDA EventsDiaMedica Therapeutics FDA EventsEntera Bio FDA EventsGalectin Therapeutics FDA EventsGilead Sciences FDA EventsJaguar Animal Health FDA EventsKalaris Therapeutics FDA EventsMicrobot Medical FDA EventsPhathom Pharmaceuticals FDA EventsQuoin Pharmaceuticals FDA EventsSilexion Therapeutics FDA EventsAbbVie FDA EventsTeleflex FDA EventsAchieve Life Sciences FDA EventsArrowhead Pharmaceuticals FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Solid Biosciences FDA Events Relmada Therapeutics FDA Events CorMedix FDA Events Design Therapeutics FDA Events Aura Biosciences FDA Events Allogene Therapeutics FDA Events Climb Bio FDA Events Candel Therapeutics FDA Events Aclaris Therapeutics FDA Events Bright Minds Biosciences FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:IMDX last updated on 3/4/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...Behind the Markets | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncocyte Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncocyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Provided Update - March 3,2026Provided Update Drug: GraftAssureDxAnnounced Date: March 3, 2026Indication: test kit clinical trial for its planned in vitro diagnostic (IVD)AnnouncementInsight Molecular Diagnostics Inc. announced that in February the company completed several major milestones to support the GraftAssureDx™ test kit clinical trial for its planned in vitro diagnostic (IVD) De Novo submission to the U.S. Food and Drug Administration (FDA) and also received its ISO 13485 certification.AI SummaryIn February, Insight Molecular Diagnostics announced several major milestones to support the GraftAssureDx test kit and its planned in vitro diagnostic (IVD) De Novo submission to the U.S. Food and Drug Administration. The company completed a three-site reproducibility study at Tampa General Hospital, Mayo Clinic, and Baylor Scott & White Health. It also said it collected what it believes are sufficient clinical samples to support the statistical analysis needed for the submission. On Feb. 26, Insight received ISO 13485 certification from TÜV SÜD. That certification confirms a regulator-aligned quality management system, helps enable near-term IVD submissions in the U.K., and paves the way for an EU IVD-R filing. The company says the certification should reduce the risk of surprises during regulatory review and lower quality risk for future manufacturing. Insight is finishing internal analytical performance testing; of roughly 12,000 instrument and assay cycles needed for the FDA package, about 340 remain. The company aims to make GraftAssureDx available for clinical use beginning in 2026 to expand access to transplant organ health testing.Read Announcement
